(FME) Fresenius Medical Care - Ratings and Ratios
Dialysis Machines, Dialyzers, Bloodlines, Concentrates, Renal Drugs
FME EPS (Earnings per Share)
FME Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 32.1% |
| Value at Risk 5%th | 46.3% |
| Reward | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha Jensen | -8.08 |
| Character | |
|---|---|
| Hurst Exponent | 0.556 |
| Beta | 0.950 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.77% |
| Mean DD | 14.09% |
Description: FME Fresenius Medical Care October 30, 2025
Fresenius Medical Care AG & Co. KGaA (XETRA:FME) is the world’s largest provider of dialysis services, operating a global network of outpatient clinics and supplying dialysis equipment, consumables, and renal pharmaceuticals to both clinics and hospitals.
The business is split into two segments: **Care Delivery**, which runs the outpatient dialysis centers and hospital contracts, and **Care Enablement**, which manufactures and distributes dialysis machines, disposables, water-treatment systems, and related renal drugs.
Key economic drivers include the growing prevalence of end-stage renal disease (ESRD) driven by aging demographics and rising diabetes rates, as well as reimbursement policies in the U.S. Medicare system that influence per-treatment pricing and volume incentives.
Recent performance metrics (FY 2023) show revenue of €21.6 bn, a 4.2 % YoY increase, and a net profit margin of roughly 6 %, reflecting both volume growth and modest pricing pressure. The company’s **dialysis-treatment volume** rose to 2.9 million sessions, while **machine sales** grew 5 % year-over-year, underscoring the dual-track strategy of service expansion and product innovation.
Sector-wide, the dialysis market is expected to expand at a CAGR of 5-6 % through 2030, with U.S. Medicare reimbursement reforms and European health-budget constraints representing the primary sources of upside or downside risk for FME.
For a deeper, data-driven look at FME’s valuation multiples, cash-flow outlook, and peer comparison, the ValueRay analysis provides a concise, research-ready overview.
FME Stock Overview
| Market Cap in USD | 15,529m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | |
| Return 12m vs S&P 500 | -7.84% |
| Analyst Rating | - |
FME Dividends
| Dividend Yield | 3.46% |
| Yield on Cost 5y | 2.25% |
| Yield CAGR 5y | -16.09% |
| Payout Consistency | 97.7% |
| Payout Ratio | 38.3% |
FME Growth Ratios
| CAGR | 13.57% |
| CAGR/Max DD Calmar Ratio | 0.37 |
| CAGR/Mean DD Pain Ratio | 0.96 |
| Current Volume | 729.8k |
| Average Volume | 671.5k |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (656.4m TTM) > 0 and > 6% of Revenue (6% = 1.17b TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 2.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.68% (prev 14.18%; Δ -1.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 2.75b > Net Income 656.4m (YES >=105%, WARN >=100%) |
| Net Debt (9.31b) to EBITDA (3.09b) ratio: 3.01 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (293.4m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 24.67% (prev 25.34%; Δ -0.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 59.88% (prev 57.28%; Δ 2.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.77 (EBITDA TTM 3.09b / Interest Expense TTM 392.3m) >= 6 (WARN >= 3) |
Altman Z'' 2.62
| (A) 0.08 = (Total Current Assets 8.14b - Total Current Liabilities 5.66b) / Total Assets 31.29b |
| (B) 0.36 = Retained Earnings (Balance) 11.29b / Total Assets 31.29b |
| (C) 0.05 = EBIT TTM 1.48b / Avg Total Assets 32.59b |
| (D) 0.59 = Book Value of Equity 9.93b / Total Liabilities 16.96b |
| Total Rating: 2.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.57
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 9.21% = 4.61 |
| 3. FCF Margin 10.52% = 2.63 |
| 4. Debt/Equity 0.83 = 2.17 |
| 5. Debt/Ebitda 3.01 = -1.78 |
| 6. ROIC - WACC (= -0.07)% = -0.09 |
| 7. RoE 4.70% = 0.39 |
| 8. Rev. Trend -25.49% = -1.91 |
| 9. EPS Trend 91.06% = 4.55 |
What is the price of FME shares?
Over the past week, the price has changed by -0.31%, over one month by -12.38%, over three months by +0.70% and over the past year by +6.80%.
Is Fresenius Medical Care a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FME is around 37.66 EUR . This means that FME is currently overvalued and has a potential downside of -9.54%.
Is FME a buy, sell or hold?
What are the forecasts/targets for the FME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.2 | 15.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 40.9 | -1.8% |
FME Fundamental Data Overview January 01, 1970
Market Cap EUR = 13.45b (13.45b EUR * 1.0 EUR.EUR)
P/E Trailing = 16.9672
P/E Forward = 10.582
P/S = 0.6849
P/B = 1.0134
P/EG = 0.4087
Beta = 0.95
Revenue TTM = 19.52b EUR
EBIT TTM = 1.48b EUR
EBITDA TTM = 3.09b EUR
Long Term Debt = 6.33b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.60b EUR (from shortTermDebt, last quarter)
Debt = 11.02b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.31b EUR (from netDebt column, last quarter)
Enterprise Value = 22.29b EUR (13.45b + Debt 11.02b - CCE 2.19b)
Interest Coverage Ratio = 3.77 (Ebit TTM 1.48b / Interest Expense TTM 392.3m)
FCF Yield = 9.21% (FCF TTM 2.05b / Enterprise Value 22.29b)
FCF Margin = 10.52% (FCF TTM 2.05b / Revenue TTM 19.52b)
Net Margin = 3.36% (Net Income TTM 656.4m / Revenue TTM 19.52b)
Gross Margin = 24.67% ((Revenue TTM 19.52b - Cost of Revenue TTM 14.70b) / Revenue TTM)
Gross Margin QoQ = 25.34% (prev 24.25%)
Tobins Q-Ratio = 0.71 (Enterprise Value 22.29b / Total Assets 31.29b)
Interest Expense / Debt = 0.88% (Interest Expense 96.6m / Debt 11.02b)
Taxrate = 22.32% (78.3m / 350.6m)
NOPAT = 1.15b (EBIT 1.48b * (1 - 22.32%))
Current Ratio = 1.44 (Total Current Assets 8.14b / Total Current Liabilities 5.66b)
Debt / Equity = 0.83 (Debt 11.02b / totalStockholderEquity, last quarter 13.27b)
Debt / EBITDA = 3.01 (Net Debt 9.31b / EBITDA 3.09b)
Debt / FCF = 4.53 (Net Debt 9.31b / FCF TTM 2.05b)
Total Stockholder Equity = 13.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.10% (Net Income 656.4m / Total Assets 31.29b)
RoE = 4.70% (Net Income TTM 656.4m / Total Stockholder Equity 13.96b)
RoCE = 7.30% (EBIT 1.48b / Capital Employed (Equity 13.96b + L.T.Debt 6.33b))
RoIC = 5.47% (NOPAT 1.15b / Invested Capital 21.03b)
WACC = 5.54% (E(13.45b)/V(24.48b) * Re(9.52%) + D(11.02b)/V(24.48b) * Rd(0.88%) * (1-Tc(0.22)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 72.77% ; FCFE base≈1.78b ; Y1≈1.75b ; Y5≈1.79b
Fair Price DCF = 85.07 (DCF Value 24.66b / Shares Outstanding 289.8m; 5y FCF grow -2.64% → 3.0% )
EPS Correlation: 91.06 | EPS CAGR: 35.20% | SUE: 0.05 | # QB: 0
Revenue Correlation: -25.49 | Revenue CAGR: -2.22% | SUE: -1.03 | # QB: 0